Perflubron - LiquiVent

Drug Profile

Perflubron - LiquiVent

Alternative Names: LiquiVent

Latest Information Update: 29 May 2001

Price : $50

At a glance

  • Originator Alliance Pharmaceutical Corporation
  • Class Fluorocarbons; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Neonatal respiratory distress syndrome; Respiratory tract disorders

Most Recent Events

  • 29 May 2001 Investigation in Respiratory tract disorders in North America (Inhalation)
  • 29 May 2001 Discontinued-III for Acute lung injury in Europe (Intrapulmonary)
  • 29 May 2001 Discontinued-III for Acute lung injury in USA (Intrapulmonary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top